Full-year 2025 preliminary1 U.S. net product revenues of $689 millionSYFOVRE® (pegcetacoplan injection) total injection demand grew 17% year-over-year; regulatory submission for prefilled syringe ...
Pfizer Inc. (NYSE: PFE) today announced positive results from Cohort 3, a separate randomized cohort of the pivotal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback